Editors & Staff
Scientific Editors
Shachi Bhatt, Executive Editor
[email protected] 
@Shachi_JExpMed
Shachi received her PhD in Anatomy and Cell Biology from University of Kansas Medical Center. She pursued her postdoctoral research in the lab of Paul Trainor at the Stowers Institute for Medical Research, where she studied the development of peripheral nervous and vascular systems, WNT/β-catenin signaling, and neural crest cell induction and differentiation. She has been a professional editor since 2017 when she joined Journal of Experimental Medicine as a scientific editor. Shachi joined Life Science Alliance as Executive Editor in August 2020, and was appointed Executive Editor of Journal of Experimental Medicine in May 2021.
Declares no conflict of interest.
Xin (Cindy) Sun, Deputy Editor
[email protected] @Cindy_JExpMed
Xin (Cindy) received her PhD from Johns Hopkins University under the supervision of Fengyi Wan, studying NF-kB signaling in T cell activation and DNA damage response during tumorigenesis. She then pursued her postdoctoral research with Robert Darnell at The Rockefeller University, focusing on RNA-protein crosstalk in neurological diseases. She joined the Journal of Experimental Medicine as a Scientific Editor in 2018 and became Deputy Editor in 2023. As Deputy Editor, Cindy leads JEM's Continuing Medical Education activities, supervises JEM Collections, and is in charge of JEM Reviews and Perspectives.
Declares no conflict of interest.
Gaia Trincucci, Deputy Editor
[email protected] @Gaia_JExpMed
Gaia received her PhD in Cell Biology from the University of Basel, Switzerland, studying the role of Type III interferons in chronic hepatitis C. She pursued her postdoctoral work with Abraham Brass and Kate Fitzgerald at University of Massachusetts Medical School, focusing on uncovering novel host factors in viral replication. She joined the Journal of Experimental Medicine as a Scientific Editor in 2018 and became Deputy Editor in 2023. As Deputy Editor, Gaia leads the commissioning and publication of JEM Viewpoints and Found in Translation and oversees strategies to promote Diversity and Inclusion at JEM.
Declares no conflict of interest.
Montserrat Cols, Senior Scientific Editor
[email protected] @Montse_JExpMed
Montserrat (Montse) received her PhD from Keele University in the UK. She then trained with Dr. Andrea Cerutti at Mount Sinai School of Medicine and more recently worked with Dr. Jayanta Chaudhuri at the Sloan Kettering Institute. Throughout her training and appointments, her particular focus has been on many aspects relating to B cell biology. Montse joined the Journal of Experimental Medicine as a Scientific Editor in 2020. Montse is in charge of the JEM volunteer program.
Declares no conflict of interest.
Lucie Van Emmenis, Senior Scientific Editor
[email protected] @Lucie_JExpMed
Lucie received her PhD from University College London, UK, under the supervision of Prof. Alison Lloyd studying the role of Schwann cells in peripheral nerve injuries. She then joined the lab of Dr. David S. Rickman at Weill Cornell Medicine where she studied the role of the microenvironment in promoting advanced prostate cancer. She joined the Journal of Experimental Medicine as a Scientific Editor in 2022 and became a Senior Scientific Editor in 2024. Lucie is in charge of JEM People & Ideas.
Declares no conflict of interest.
Zhijuan Qiu, Scientific Editor
[email protected] @Zhijuan_JExpMed
Zhijuan (pronounced zee-jen) received her PhD from the University of Connecticut Health Center, where she focused on developing T cell-based cancer vaccines and understanding the role of pregnane X receptor in innate immunity under the supervision of Dr. Kamal Khanna. After obtaining her PhD, Zhijuan went on to study the role of follicular helper T cells and CD8 T cells during influenza infection in the lab of Dr. Laura Haynes at the University of Connecticut Health Center for a year, and memory CD8 T cell development in the lab of Dr. Brian Sheridan at Stony Brook University. Zhijuan joined Communications Biology as an Associate Editor in February 2022 before joining the Journal of Experimental Medicine as a Scientific Editor in March 2023.
Declares no conflict of interest.
Gabriele Stephan, Scientific Editor
Gabriele received her PhD in biochemistry from Leipzig University in Germany, where she investigated the role of ion channels in pain transmission under the supervision of Prof. Peter Illes. She then spent a year in Dr. Ines Liebscher’s lab at Leipzig University to study activation mechanisms of adhesion GPCRs. She pursued her postdoctoral training in the lab of Dr. Dimitris Placantonakis at NYU Langone, focusing on the role of an adhesion GPCR in glioblastoma. Gabriele joined the Journal of Experimental Medicine as a Scientific Editor in 2024.
Declares no conflict of interest.
Editorial Board Co-Chairs
Carl Nathan, Editorial Board Co-Chair
Carl Nathan is an R.A. Rees Pritchett Professor of Microbiology and Chairman of the Department of Microbiology and Immunology at Weill Cornell Medicine. After studying and working at Harvard College, Harvard Medical School, Massachusetts General Hospital, the National Cancer Institute, and Yale, Carl was board certified in internal medicine and oncology but decided on full-time research. For the first 10 years, his lab was in Zanvil Cohn’s group at The Rockefeller University. He then moved to the medical college at Cornell, where he has served as founding director of the Tri-Institutional MD-PhD Program, Senior Associate Dean for Research, Acting Dean, Chairman of the Department of Microbiology and Immunology, co-chair of the program in Immunology and Microgial Pathogenesis in the Weill Cornell Graduate School of Medical Sciences, and dean of the graduate school. Nathan began studying neutrophils in high school. His interests grew to include macrophages, tumor cells, inflammation, tuberculosis, reactive oxygen intermediates, reactive nitrogen intermediates, immunology, biochemistry, and chemical biology. Carl joined the editorial board of the Journal of Experimental Medicine as an Assistant Editor in 1981 and has been an Academic Editor since 1988.
Scientific advisory boards: Cancer Research Institute, Rita Allen Foundation, Lurie Prize jury for Foundation for the NIH, Leap Therapeutics
Governing boards: Tres Cantos Open Lab Foundation, Tri-Institutional Therapeutics Discovery Institute, Rita Allen Foundation
Editorial boards: Journal of Experimental Medicine, Proceedings of the National Academy of Sciences, Science Translational Medicine.
Founder and advisor: IpiNovyx Bio, Inc.
Consultant: Third Pole, Inc.
Patents: Compounds that target M. tuberculosis and P. falciparum and immunoproteasomes.
Funding sources: the Nathan lab receives grants from the National Institutes of Health and Bill & Melinda Gates Foundation and has a collaborative research agreement with the Global Alliance for TB Drug Development.
Michel Nussenzweig, Editorial Board Co-Chair
Michel Nussenzweig is a Sherman Fairchild Professor, Senior Physician, and a Howard Hughes Investigator at The Rockefeller University. Michel earned a PhD from The Rockefeller University for his work with Ralph Steinman on dendritic cells and an MD from NYU Medical School. Following training in medicine and infectious diseases at the Massachusetts General Hospital, he worked with Dr. Philip Leder in the Department of Genetics at Harvard Medical School on antibody genes. His laboratory focuses on understanding B cell and dendritic cell physiology. Michel became an Academic Editor of the Journal of Experimental Medicine in 1995.
Scientific Advisory Board: CellDex Therapeutics, Frontier Biotechnology, the Austrian Academy of Sciences, and the Jackson Laboratory.
Editorial Boards: Journal of Experimental Medicine and Journal of Immunological Methods.
Patents: Rockefeller University owns patents for the 3BNC117 antibody being developed by Frontier Biotechnology. Michel Nussenzweig is an inventor on patents for antibodies to HIV-1 that have been licensed to Gilead by Rockefeller University. The Rockefeller University has applied for patents on SARS-2 antibodies on which Michel Nussenzweig is an inventor. The Rockefeller University has licensed the SARS-2 antibodies to Bristol Meyers Squibb.
Funding sources: the Nussenzweig laboratory receives research grants from the National Institutes of Health, The Bill and Melinda Gates Foundation, The Lyda Hill Foundation, The Wennett Cader Foundation, The Robertson Fund of the Rockefeller University. Dr. Nussenzweig is an HHMI investigator.
Academic Editors
Jean-Laurent Casanova, Editor
Jean-Laurent Casanova is the Levy Family Professor at The Rockefeller University, Howard Hughes Medical Institute Investigator, and Head of the St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch. He is also a Professor at the Necker Hospital for Sick Children, Paris Cité University, where the Necker Branch of the Laboratory is located. Jean-Laurent received his PhD from the Pierre et Marie Curie Paris University in 1992 after being trained at the Pasteur Institute in Paris and the Ludwig Institute for Cancer Research in Lausanne. He received his MD in 1995 following medical studies and a residency in pediatrics in Paris. He then completed a clinical fellowship in the pediatric immunology−hematology unit of the Necker Hospital for Sick Children in Paris. In 1999 he was appointed a Professor of Pediatrics at Necker, where, with Laurent Abel, he cofounded and co-directed the Laboratory of Human Genetics of Infectious Diseases. He was recruited by the Rockefeller University in 2008 and appointed an Investigator at the Howard Hughes Medical Institute in 2014. Work in his laboratory focuses on identifying inherited disorders and their autoimmune phenocopies that selectively compromise immunity to a single infection in otherwise healthy children and adults. He has identified single-gene inborn errors of type I and type II IFN immunity, as well as auto-antibodies neutralizing type I and type II IFNs, which respectively underlie viral and intra-macrophagic infections. Jean-Laurent became an Academic Editor of the Journal of Experimental Medicine in 2006.
Scientific advisory boards/consulting: ADMA, Celgene, Elixiron Immunotherapeutics, KymeraTX, Mirimus.
Editorial boards: Current Opinion in Immunology, Journal of Experimental Medicine.
Patent applications: Inventor on a pending patent application that covers diagnosis of susceptibility to, and treatment of, viral disease and viral vaccines, including Covid-19 and vaccine-associated diseases. This pending patent application is currently not licensed.
Funding sources: the Casanova lab receives research grants from the National Institutes of Health, the Lupus Research Alliance, the St. Giles Foundation, and the French National Research Agency (ANR).
Sara Cherry, Editor
Sara Cherry is a Professor in the Department of Pathology and Laboratory Medicine and the Department of Biochemistry and Biophysics, Scientific Director of the High-throughput Screening Core and Director of the Chemogenomic Discovery Program in the School of Medicine at the University of Pennsylvania. She obtained her BS with Dr. Peter Schultz at Berkeley synthesizing new biopolymers for drug scaffolds, and then her PhD with Dr. David Baltimore at MIT studying early B cell development. Next, she completed her postdoctoral fellowship with Dr. Norbert Perrimon where she developed high-throughput RNAi screening to study virus-host interactions. She started her laboratory at Penn in 2006 where she has applied cell-based screening approaches to discover mechanisms by which diverse viral pathogens hijack cellular machinery while evading innate immune defenses. Sara joined JEM as an Academic Editor in 2020.
Funding sources: the Cherry lab receives grants from the National Institutes of Health, Mark Foundation, and the Burroughs Wellcome Fund. The Cherry lab has a collaborative research agreement with Merck.
Jonathan Kipnis, Editor
Dr. Jonathan (Jony) Kipnis is BJC Investigator, Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology at Washington University in St. Louis, School of Medicine. He is also an inaugural Director of the Brain immunology and Glia (BIG) Center. Before his move to Washington University, Dr. Kipnis was professor and chair of Neuroscience department at the University of Virginia.
Jony graduated from the Weizmann Institute of Science in Israel, where he was a Sir Charles Clore scholar. Kipnis lab focuses on the complex interactions between the immune system and the central nervous system (CNS). The fascination with immunity and its role in neurophysiology is what brought the team to a discovery of meningeal lymphatic vessels that drain the CNS into the peripheral lymph nodes and thus serve as a physical connection between the brain and the immune system. This finding challenged the prevailing dogma of CNS being an “immune privileged organ” and opened new avenues to mechanistically study the nature of neuroimmune interactions under physiological and pathological conditions. Dr. Kipnis is a recipient NIH Director’s Pioneer award for 2018 and a member of the National Academy of Medicine. Jony joined Journal of Experimental Medicine as an academic editor in 2021.
Scientific advisory board/consulting: PureTech Health, Ionis
Editorial boards: Journal of Experimental Medicine, Trends in Immunology, Brain.
Funding sources: NIH, Cure Alzheimer’s Fund, Ludwig Family foundation, BJC Health, Corsalex, Neuroscience Innovation Foundation
Lewis L. Lanier, Editor
Lewis L. Lanier is the J Michael Bishop MD Distinguished Professor Emeritus of Microbiology and Immunology at the University of California, San Francisco. Lewis received his PhD in microbiology and immunology from the University of North Carolina at Chapel Hill. After postdoctoral studies, first at the Lineberger Cancer Center at UNC Chapel Hill and then as a Damon Runyon−Walter Winchell Cancer Research Fellow at the University of New Mexico, he joined the Research & Development Department at the Becton Dickinson Monoclonal Center in Mountain View, California, advancing to Associate Director of Research, and was a Becton Dickinson Research Fellow. In 1990, he joined the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California, where he advanced to Director of Immunobiology. In 1999, Lewis joined the faculty of UCSF. His research group studies natural killer (NK) cells, which recognize and eliminate cells that have become transformed or infected by viruses. Lewis has been an Academic Editor of the Journal of Experimental Medicine since 2008.
Scientific Advisory Board: Catamaran, Cullinan Oncology, Dragonfly, DrenBio, Edity, GV20, Hinge, IMIDomics, InnDura Therapeutics, Innovent, Nkarta, Obsidian Therapeutics, SBI Biotech
Editorial Boards: Journal of Experimental Medicine, Proceedings of the National Academy of Sciences, Cancer Immunology Research.
Patents:U.S. Patents #6,140,076, #6,416,973, #6,479,638 B1, #6,953,843 B2, #7,319,140, #7,332,574, #7,659,093, #7,999,078, #7,998,481, #8,637,011, #9,211,328, #9,683,996.
Funding sources: NIAID.
William A. (Bill) Muller, Editor Emeritus
William A. Muller is the Magerstadt Professor and Chairman of the Department of Pathology at Northwestern University Feinberg School of Medicine. He received his PhD degree from The Rockefeller University and an MD degree from Cornell University Medical College. He did residency/postdoctoral fellowship training at the Massachusetts General Hospital and Brigham and Women’s Hospital in Boston before returning to Rockefeller and Cornell to set up his own laboratory. Bill was recruited to Northwestern in 2007. His research interests focus on the cellular and molecular biology of the inflammatory response, particularly from the perspective of the vascular endothelial cell. His laboratory focuses on leukocyte−endothelial cell interactions and the role of the endothelial cell in regulating inflammation with the aim of designing more selective antiinflammatory therapies. Bill has played several major leadership roles in the American Society for Investigative Pathology and the North American Vascular Biology Organization. He has been on the editorial board of the Journal of Experimental Medicine since 1993 and became an Academic Editor in 1996.
Patents: Inventor on two patents currently held with Weill Cornell Medical School relating to the use of blocking CD99 and CD99L2, respectively as anti-inflammatory agents. These are currently not licensed. Two additional patents with Northwestern currently pending.
Royalties: Bill Muller receives royalties from Rockefeller University related to the licensing of the anti-CD31 monoclonal antibody hec7.
Funding sources: The Muller lab receives grants from the National Institutes of Health (NHLBI and NCI) and the Lefkofsky Family Foundation.
Anne O’Garra, Editor
Anne O'Garra is a Senior Group Leader of the Laboratory of Immunoregulation and Infection, and Associate Research Director, at The Francis Crick Institute, London. From 2001–2015, Anne was the Head of the Division of Immunoregulation at the National Institute for Medical Research (NIMR), Mill Hill, London, UK, now part of The Francis Crick Institute. Anne obtained her PhD at the NIMR working on bacterial adhesion and then moved fields and joined the Division of Immunology at NIMR as a Postdoctoral Fellow, where she studied the role of cytokines in B cell growth and differentiation. Anne moved to California in 1987, where she spent 15 years at the DNAX Research Institute. There, Anne's laboratory delineated mechanisms for the development of discrete subsets of CD4+ T cells and showed that this is determined by a number of factors, including cytokines, dose and form of antigens, and the antigen-presenting cells. A major focus of her work has been on the mechanisms for induction of the suppressive cytokine IL-10 and the function of this cytokine to regulate immune responses. Anne continues her research to interface immunology and infectious diseases, continuing to research the role and regulation of cytokines in immunoregulation, with a focus on the immune response in tuberculosis in mouse models and in human disease. Anne became an Academic Editor of the Journal of Experimental Medicine in 2004.
Scientific advisory boards: Keystone Conferences, USA; Kennedy Institute of Rheumatology, University of Oxford; MRC Weatherall Institute of Molecular Medicine, University of Oxford; National Research Foundation (NRF), Singapore; Jury Novartis Prizes for Immunology; Jury for the Sanofi – Institut Pasteur awards, France
Funding Sources: The O’Garra lab receives research grants from the The Francis Crick Institute which receives its core funding from Cancer Research UK (FC001126), the UK Medical Research Council (FC001126), and the Wellcome Trust (FC001126); Bioaster Microbiology Technology Institute, Lyon, France; Medical Diagnostic Discovery Department, bioMérieux SA, Marcy l’Etoile, France; and funded in part by Illumina Inc., San Diego, CA, USA; and O’Garra is soon to receive a Wellcome Investigator award.
Emmanuelle Passegué, Editor
Emmanuelle Passegué, PhD, is an Alumni Professor of Genetics and Development and Rehabilitation Medicine and the Director of the Columbia Stem Cell Initiative at Columbia University Medical Center. Before her recent move to Columbia University, Emmanuelle was Professor of Medicine in the Hematology/Oncology Division and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, San Francisco. She received her PhD from the University Paris XI in France and performed postdoctoral trainings with Dr. Erwin Wagner at the Institute for Molecular Pathology in Austria and Dr. Irv Weissman at Stanford University. Emmanuelle’s research interests focus on the biology of blood-forming hematopoietic stem cells (HSCs) in normal and deregulated contexts such as stress, malignancies, and aging. She has received numerous Scholar Awards from the American Society of Hematology, the Rita Allen Foundation, the California Institute for Regenerative Medicine, and the Lymphoma and Leukemia Society. Emmanuelle joined JEM as Academic Editor in 2017.
Scientific advisory board/consulting: Damon Runyon Fellowship Award Committee (FAC), President Elected of the International Society of Experimental Hematology, active committee roles with ASH, ISSCR and ISEH.
Editorial boards: member of the Cell Stem Cell editorial board and scientific editor for BLOOD CANCER DISCOVERY.
Patents: Emmanuelle Passegué is an inventor on a patent licensed by Stanford University to the Jackson Laboratory for the commercialization of the MRP8-Cre-ires-GFP mice.
Funding sources: the Passegué lab receives research grants from the National Institute of Health, the Leukemia Lymphoma Society and the Glenn Foundation.
Alexander Rudensky, Editor
Alexander Rudensky is an HHMI Investigator and a member of the Department of Immunology at Memorial Sloan Kettering Cancer Center. Prior to his recent move to Sloan Kettering, he was Professor of Immunology at the University of Washington School of Medicine, Seattle, and Adjunct Professor at the A.N. Belozersky Institute of Physico-Chemical Biology, Moscow State University, Russia. Dr. Rudensky received his PhD degree from the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow. After postdoctoral training at Yale University Medical School with Charles Janeway, he remained as an associate research scientist. Dr. Rudensky was a Searle Scholar and received a Pharmingen Investigator Award from the American Association of Immunologists.
Alexander Rudensky is studying the development of T lymphocytes, their function, and their role in the regulation of immune responses to infection and in the prevention of autoimmunity. His studies include investigation of the control of immune homeostasis by regulatory T cells and investigation of the molecular mechanisms instructing commitment of specialized T cell lineages.
Scientific advisory boards/consulting: SAB: Sonoma Biotherapeutics, RAPT Therapeutics, Vedanta Biosciences, BioInvent, Amgen, Merck, Santa Ana Bio, Almirall, Coherus (formerly Surface Oncology), Cancer Research Institute.
Patents: Dr. Rudensky is a co-inventor on, and receives royalties from patents, filed by MSK, related to anti-CCR8 antibodies for the treatment of cancer.
Funding sources: the Rudensky lab receives research grants from the National Institutes of Health. Dr. Rudensky is a Howard Hughes Medical Investigator and receives support for the overall research of the laboratory.
Arlene Sharpe, Editor
Arlene Sharpe MD PhD is the Kolokotrones University Professor at Harvard University and Chair of the Department of Immunology at Harvard Medical School.
Dr. Sharpe earned her A.B. from Harvard University and her M.D. and Ph.D. degrees from Harvard Medical School. She completed residency training in Pathology at Brigham and Women’s Hospital and is board certified in Anatomic Pathology.
Dr. Sharpe is a leader in the field of T cell costimulation. Her laboratory has discovered and elucidated functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways, which are targets for cancer immunotherapy. Her laboratory currently investigates roles of T cell costimulatory pathways in cancer, autoimmunity, and infection. Dr. Sharpe has published over 300 papers and was listed by Thomas Reuters as one of the most Highly Cited Researchers (top 1%) in 2014-2018 and a 2016 Citation Laureate. She received the William B. Coley Award for Distinguished Research in Tumor immunology in 2014 and the Warren Alpert Foundation Prize in 2017 for her contributions to the discovery of PD-1 pathway. Dr. Sharpe is an elected member of the National Academy of Sciences and National Academy of Medicine and a Fellow of the American Association for Cancer Research.
Scientific advisory boards/consulting: Elpiscience, Selecta, Bicara, Monopteros, Fibrogen, IOME, Alixia, Corner Therapeutics, Bioentre, GlaxoSmithKline, Janssen and Amgen, Massachusetts General Cancer Center, Program in Cellular and Molecular Medicine at Boston Children's Hospital, the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, the Gladstone Institute, and the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy.
Editorial Board: Journal of Experimental Medicine.
Patents: patents and/or pending royalties on the PD-1 pathway from Roche/Genentech and Novartis.
Funding sources: The Sharpe lab receives research grants from the National Institutes of Health, Department of Defense, the Melanoma Research Alliance, KBF Canada, AbbVie, Quark/Iome , TaiwanBio and Harvard University.
Alan Sher, Editor Emeritus
Alan Sher is a Senior Investigator at the National Institute of Allergy and Infectious Diseases, NIH, where he heads the Laboratory of Parasitic Diseases. Alan obtained his PhD from the University of California, San Diego, for work done in the laboratory of Melvin Cohn, and he did postdoctoral training at the National Institute for Medical Research, Mill Hill, in the UK. He was a Research Associate and then Assistant Professor in the Department of Pathology at Harvard Medical School before joining the NIH. His group’s major interest has been in mechanisms of host resistance and immune regulation in parasitic and mycobacterial infections. Alan became an Academic Editor of the Journal of Experimental Medicine in 2007.
David Tuveson, Editor
David Tuveson is the Director of the Cold Spring Harbor Laboratory (CSHL) Cancer Center, the Roy J. Zuckerberg Professor of Cancer Research at CSHL, the head of the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, and is also the Lustgarten Foundation’s Director of Research. Dr. Tuveson completed a bachelor's degree at MIT (Chemistry, 1987), the MD-PhD program at Johns Hopkins in 1994, an Internal Medicine residency at Brigham and Women's Hospital in 1997, and a Medical Oncology fellowship at Dana-Farber/Harvard in 2000. While at Dana-Farber, he co-developed Gleevec/Imatinib with George Demetri as a new treatment for patients with gastrointestinal stromal tumors (GIST). Dr Tuveson completed a postdoctoral fellowship with Tyler Jacks at MIT, where he developed several mouse cancer models and investigated GIST. He was appointed assistant Professor of Medicine at the University of Pennsylvania from 2002 to 2006, where his laboratory developed the ductal pancreatic cancer models. Dr. Tuveson moved in 2006 to the CRUK/Cambridge Research Institute at the University of Cambridge to establish a preclinical therapeutics laboratory and a pancreatic cancer clinical trials group. In Cambridge, his laboratory determined several mechanisms that contribute to drug resistance in pancreatic cancer, stimulating clinical trials in these areas. He was appointed Professor of Pancreatic Cancer Medicine at the University of Cambridge and Founder of the Pancreatic Cancer Centre. In 2012, Dr. Tuveson moved to Cold Spring Harbor Laboratory as Professor and director of the Cancer Therapeutics Program. His honors include the Rita Allen Foundation Scholar Award, the Waldenstrom Award (2014), the Hamdan Award (2016), and election to the American Society of Clinical Investigation (2016).
Disclosure statement: David Tuveson is a shareholder of Leap Therapeutics and Surface Oncology.
Scientific advisory boards/consulting: Leap Therapeutics, Surface Oncology, Bethyl Laboratory, ONO, Lustgarten Foundation, AACR, Stand up to Cancer, Georg-Speyer-Haus.
Patents: David Tuveson is an inventor on a patent licensed by Cold Spring Harbor Laboratory to BioNTech regarding CA19-9 antibodies for treatment and prevention of pancreatitis.
Funding sources: the Tuveson lab receives research grants from the National Institutes of Health, the Lustgarten Foundation, the V Foundation.
Jedd D. Wolchok, Editor
Jedd D. Wolchok, MD, PhD, FASCO is Chief of the Melanoma Service and holds The Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK). He is also head of the Swim Across America - Ludwig Collaborative Laboratory; Associate Director of the Ludwig Center for Cancer Immunotherapy (LCCI); SU2C–ACS Lung Cancer Dream Team Co-leader and Director of the Parker Institute for Cancer Immunotherapy at MSK. Dr. Wolchok is a clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. He specializes in the treatment of melanoma. The focus of his translational research laboratory is to investigate innovative means to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies.
Consultant for: Adaptive Biotech; Advaxis; Amgen; Apricity; Ascentage Pharma; Astellas; Beigene; Bristol Myers Squibb; Celgene; Chugai; Elucida; Eli Lilly; F Star; Genentech; Imvaq; Linneaus; MedImmune; Merck; Neon Therapuetics; Ono; Polaris Pharma; Polynoma; Psioxus; Puretech; Recepta; Trieza; Sellas Life Sciences; Surface Oncology.
Co-Founder and Shareholder: Tizona Pharmaceuticals; Trieza, Imvaq Therapeutics
Equity in: Adaptive Biotechnologies; Elucida; Beigene; Trieza; Linneaus. Kleo
Scientific Advisory Board member and Shareholder: Beigene
Patents: Xenogeneic DNA Vaccines; ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2;Myeloid-derived suppressor cell (MDSC) assay; NEWCASTLE DISEASE VIRUSES FOR CANCER THERAPY; Genomic Signature to Identify Responders to Ipilimumab in Melanoma; Engineered Vaccinia Viruses for Cancer Immunotherapy; Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; CAR+ T cells targeting differentiation antigens as means to treat cancer; Anti-PD1 Antibody; Anti-CTLA4 antibodies; Anti-GITR antibodies and methods of use thereof.
Funding sources: the Wolchok lab receives funds from Bristol Myers Squibb; Genentech; Medimmune. The Wolchok lab receives grants from the NIH.
Consulting Biostatistical Editor
Xi Kathy Zhou, Consulting Biostatistical Editor
Xi Kathy Zhou is an Associate Professor of Biostatistics at Weill Cornell Medical College. She received her PhD degree in Statistics and Decision Sciences from Duke University. Her research interest is to develop and apply novel statistical methods to better design biological and clinical studies related to disease prevention, diagnosis and treatment and properly analyze data generated from such studies. Her methodological interest include Bayesian hierarchical models, model selection, model averaging, predictive modeling, and their applications to large complex datasets. She collaborates extensively with laboratory researchers and clinicians and has served as the Lead Biostatistician in clinical trials. Kathy became the Consulting Biostatistical Editor of the Journal of Experimental Medicine in 2016.
Consulting Bioinformatics Editor
Yuri Pritykin, Consulting Bioinformatics Editor
Yuri Pritykin is an assistant professor of computer science and genomics at Princeton University and an associate member at the Rutgers Cancer Institute of New Jersey. He received PhD in computer science from Princeton University and MSc and PhD in mathematics from Lomonosov Moscow State University, and did postdoctoral training at Memorial Sloan Kettering Cancer Center. His lab develops computational methods for design and analysis of high-throughput functional genomic assays and perturbations, with a focus on multi-modal single-cell, spatial and genome editing technologies, and applies these methods to study regulatory genomics of cell function and cell-cell interactions in vivo, with a focus on immunology and cancer. He is the recipient of the NIH/NIAID DP2 New Innovator Award (2022), the NSF CAREER Award (2023), the Rutgers Cancer Institute of New Jersey New Investigator Award (2021) and the AACR-Bristol-Myers Squibb Immuno-oncology Research Fellowship (2019). Yuri became the Consulting Bioinformatics Editor for Journal of Experimental Medicine in 2024.
Declares no conflict of interest.
Funding sources: NIH, NSF, Ludwig Cancer Research, Princeton University, Rutgers Cancer Institute.
Associate Editors
María Casanova-Acebes, Associate Editor
Since January 2021 María Casanova-Acebes is a Junior Group Leader at the Centro Nacional de Investigaciones Oncológicas (CNIO, Madrid), leading the Laboratory of Cancer Immunity. As a graduate student with Andrés Hidalgo at CNIC, she established for the first time how circadian cues control neutrophil aging and clearance from circulation, which in turn control the physiology of hematopoietic and metastasis-prone organs such as the bone marrow, and the lung (Cell 2023, JEM 2018). Awarded a Human Frontiers Long-Term postdoctoral fellowship, she then moved to Mount Sinai School of Medicine in New York to carry out her postdoctoral studies under the supervision of Miriam Merad, where she discovered that resident macrophages in the lung control early regulatory T cell expansion and EMT programs in lung cancer (Nature 2021).
The Casanova-Acebes lab investigates how micro- and macro-environmental factors shape myeloid cells in tumors, intending to uncover new actionable targets in this compartment to treat cancer. As of 2024, María Casanova-Acebes has published >20 articles in top scientific journals, which have been cited > 5,000 times. She hasreceived several prizes and awards, including an ERC Starting Grant in 2023. Maria is actively involved in public outreach and research dissemination projects, and she has been recently selected as a member of the Spanish Young Academy in 2023. In her (little!) spare time, María is a passionate reader and loves playing with her kids.
David Gate, Associate Editor
Dr. David Gate is the director of the Abrams Research Center on Neurogenomics in the Feinberg School of Medicine at Northwestern University. Dr. Gate is a neuroimmunologist who studies neuroinflammatory mechanisms of neurodegenerative diseases. His research has contributed to our understanding of the role of immune responses in Alzheimer’s disease. Recently, his group has been exploring the impact of anti-amyloid antibodies on microglial function.
COI: Dr. Gate has served as a paid consultant for Merck and Novo Nordisk related to anti-inflammatory therapeutics for Alzheimer’s disease.
Elisa Oricchio, Associate Editor
Elisa Oricchio is the Director of the Swiss Institute for Experimental Cancer Research (ISREC) and a professor at EPFL in Lausanne (Switzerland). She received her Ph.D. in 2008 in Italy, and did her post-doctoral training at Memorial Sloan Kettering Cancer Center in New York, where she gained expertise in cancer genomics, genetic manipulation of transgenic animal models, and pre-clinical treatment studies. Currently, her research focuses on cancer genome organization in the 3D space. She is also developing new models to study responses to therapy and use high throughput screening to identify new therapeutic targets. In her work she combined experimental and computational analyses to understand and ultimately block the tumor’s origin and progression. Throughout her career, she has identified genes that can be used as new therapeutic targets or as biomarkers to classify cancer patients better. Her work has been recognized internationally with the European Translational Cancer Research Award, the Prix Leenaards for Translation Research, the Blavatnik Award for Young Scientist by the New York Academy of Science, and the Lorini Award for Italian Scientist in Cancer Research.
Board member of the European Association of Cancer Research (EACR); Scientific Advisory Board of QMUL Centre for Epigenetics, Barts, London, UK; and Member of the executive committee for the Swiss National Initiative on Personalized Health and Retaliated Technology.
Tim O’Sullivan, Associate Editor
Tim O’Sullivan, PhD, is an Associate Professor in the Department of Microbiology, Immunology and Molecular Genetics at the University of California, Los Angeles. His laboratory aims to understand how the innate immune system is regulated during inflammation. Using systems approaches, the O’Sullivan lab uses clinical datasets and gene editing to predict and validate critical pathways that regulate human innate immunity. Targets are engineered using CRISPR tools to facilitate the development of next generation cellular and in vivo gene editing therapies for autoimmunity, immune deficincies, and cancer. Tim joined JEM as Associate Academic Editor in 2025.
Scientific advisory boards/consulting: Xyphos Biosciences Inc., Algen Bio, Modulus Therapeutics, AlphaSights, Rare Bird Foundation
Editorial Boards: Advisory Board, Cell Reports. Associate Academic Editor, Journal of Experimental Medicine.
Funding sources: the O’Sullivan lab receives research grants from the National Institutes of Health and the Hypothesis Fund.
Ashley St. John, Associate Editor
Dr. Ashley St. John is an Associate Professor in the Programme in Emerging Infectious Diseases at Duke-NUS Medical School. She also holds appointments in the Department of Microbiology and Immunology, National University of Singapore, the Department of Pathology, Duke University and the SingHealth Duke-NUS Global Health Institute. In 2023, she received an Investigatorship award from the National Research Council of Singapore. Her research program focuses on viral immunology with emphasis on developing novel vaccination strategies, diagnostics, and therapeutics for infectious diseases. She also studies immune responses at the intersection of infectious and allergic diseases, particularly involving the role of mast cells.
Tuoqi Wu, Associate Editor
Tuoqi Wu is an assistant professor in the Department of Immunology at the University of Texas Southwestern Medical Center, a member of the Harold C. Simmons Comprehensive Cancer Center, and an investigator of the O'Donnell Brain Institute. He received his Ph.D. degree in 2013 studying the regulation of antiviral T cell immunity by microRNAs under the supervision of Dr. Rafi Ahmed at Emory University. He then completed his postdoctoral training in transcriptional regulation of T cell stemness and exhaustion with Dr. Pamela Schwartzberg at the National Institutes of Health. He started his independent research group in 2019. His research interests focus on how chronic infection, cancer and aging dysregulates T cell immunity and how to reinvigorate T cells by harnessing their differentiation program. He received the V Scholar Award, the ASPIRE Award for Outstanding Early Career Investigators, and the ICIS-Regeneron New Investigator Award.
Funding sources: National Institutes of Health, U.S. Department of Defense, V Foundation, Cancer Research Institute, American Federation for Aging Research
Declares no conflict of interest.
Staff
Sylvia Cuadrado, Senior Managing Editor
Sylvia has worked at The Rockefeller University Press since 2005.
Elissa Hunter, Assistant Production Editor
Elissa Hunter joined Rockefeller University Press in July 2020 after more than a decade of working as a copy editor and proofreader, most recently at Marvel Entertainment and The Culture Trip. She has a BS in journalism from University of Florida, an MLIS from Pratt Institute, and no idea how she ended up with two science degrees.
Jennifer McGullam, Production Editor
Jenny joined Rockefeller University Press in 2018. She has been working in scientific and medical publishing for several years, most recently as a Production Editor at Springer Nature. Jenny studied English and linguistics at Dartmouth College and enjoys baking, reading, and exploring the outdoors.
Rochelle Ritacco, Preflight Editor
Rochelle is responsible for the preparation of figures for RUP publication—checking production quality, conforming style, and clarity of presentation. She is a skilled digital artist with expertise in many media applications. Rochelle began freelancing at RUP in 2007 and shortly thereafter joined the staff. Prior to RUP, she assisted the campus photographer at Monmouth University. Rochelle received her BA in communications from Seton Hill University and has completed two certificate programs, Digital Art (BCC) and Filmmaking (NYU). She is on the board of the Belmar Art Council. Rochelle lives along the dazzling north Jersey shore with her husband and daughter.
Laura Smith, Senior Preflight Editor
Laura began her career at The Rockefeller University in 1996 in the Office of Public Affairs. In 1997, she joined the RU Press as assistant to then director Michael Held. In 2002, under the guidance of Mike Rossner, Laura began image screening. She has since traveled abroad and throughout the United States training others in the detection of image manipulation. Laura lives in the Hudson Valley with her daughter and rescue kitty "Wiki".
